Background: We aim to explore the relationship between minimum point dose (D min ) to the primary gross tumor volume (GTV_P) and local control in treating T3-4 nasopharyngeal carcinoma (NPC). Methods: Ninety-six non-metastatic T3-4 NPC patients were enrolled between January 2009 and November 2013. Intensity-modulated radiation therapy (IMRT) plus docetaxel, cisplatin and fluorouracil (TPF) chemotherapy was administered. The prescribed dose was 66-70.4 Gy to the GTV_P while maintaining all the critical neurologic organs within dose constraints. Results: The local response rate was 88.6% after induction chemotherapy. With a median followup of 48.5 months, the 3-year local failure-free survival (LFFS) and overall survival (OS) rates were 92.4% and 89.6%, respectively. The average D min to the GTV_P was 59.4 Gy (range,. Additionally, 54.0 Gy was identified as the optimal cut-off D min to the GTV_P, and the D min ≥54.0 Gy group had a better local complete response rate after IMRT (52.4% vs. 81.3%, χ 2 = 7.335, P = 0.007), a
Introduction
Over time, the technology of intensity-modulated radiation therapy (IMRT) has become widely accepted in clinical practice as the treatment for nasopharyngeal carcinoma (NPC) (1, 2) . With the advantages of better dosimetry coverage and higher conformal dose distributions to targets while sparing organs at risk (OAR) compared with two-dimensional radiotherapy, the implementation of IMRT has resulted in satisfactory benefits in local control for NPC patients (3, 4) . Although IMRT can achieve excellent 5-year local control rates ≥95% for T1-2 disease, the corresponding rates are poor for T3-4 disease, ranging from 83% to 87.5% (5) (6) (7) (8) .
For patients with T3-4 NPC, experts have attempted to improve local control by the addition of chemotherapy and dose escalation. The benefits of chemotherapy have been demonstrated by prospective and retrospective studies (9) (10) (11) , but the role of dose escalation warrants discussion. The minimum point dose (D min ) to the primary gross tumor volume (GTV_P) has been reported to be an independent prognostic predictor of the local control rate (12, 13) . Researchers have found that dose escalation may lead to better local control but with increased late toxicities as well. Some patients may even develop severe, life-threatening complications (14, 15) . In addition, it is difficult to increase the D min to the GTV_P in T3-4 NPC because of the proximity of the nasopharynx to critical neurologic tissues, such as the brain stem, temporal lobes, optic chiasm and nerves. For the dose to the surrounding neurologic tissues to be kept within an acceptable range, radiation field coverage and dose to GTV_P will inevitably be compromised. Therefore, the optimal balance between the D min to the GTV_P and protection of OAR must be explored. A prospective observational study for the treatment of T3-4 NPC with IMRT plus chemotherapy was performed to investigate the relationship between local control and late toxicities and the optimal D min to the GTV_P, without exceeding the dose constraint criteria for neurologic tissues.
Materials and methods

Patients and pretreatment evaluation
Inclusion criteria were as follows: (1) aged between 18 and 70 years; (2) newly histologically confirmed non-keratinizing NPC according to a biopsy; (3) no evidence of distant metastasis; (4) no previous treatment for NPC; (5) a Karnofsky performance score ≥70; (6) the absence of pregnancy or lactation; (7) the absence of a previous malignancy or other concomitant malignant disease and (8) adequate hematologic function [total leukocyte count (WBC) ≥4000/mm 3 and platelets ≥100 000/mm 3 ], adequate hepatic and renal function [bilirubin <1.5 mg/dl, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤1.5 times the upper limit of the normal value, serum creatine (Scr) ≤1.5 mg/dl, creatinine clearance rate (CCr) ≥50 ml/min].
All the eligible T3-4 NPC patients were enrolled and restaged according to the AJCC 2010 staging classification (16) . Routine workups comprised recording a medical history, a physical examination, blood chemistry tests, chest X-ray/computed tomography (CT), abdominal ultrasound/CT, enhanced magnetic resonance imaging (MRI) of the nasopharynx and neck, nasopharyngoscopy and bone emission CT. Additional investigations were only performed for those with suspicious findings. Dental extraction, if deemed necessary, was performed prior to radiation therapy. This study was approved by our institution's ethics committee (reference number 1 410 140-8). All the patients signed informed consent forms before entering the study.
Procedures
Enrolled patients were assigned to receive two cycles of docetaxel, cisplatin and fluorouracil (TPF) induction chemotherapy (IC) followed by radiotherapy with two cycles of TPF adjuvant chemotherapy (AC). The TPF chemotherapy was administered as follows: docetaxel 60 mg/m 2 /day, Day 1; cisplatin 25 mg/m 2 /day, Days 1-3;
and 5-fluorouracil 0.5 g/m 2 /day with a 120-h infusion. The two cycles of IC were administered with an interval of 3 weeks. Four weeks after the completion of radiotherapy, AC was administered.
All the patients received adequate antiemetic medications during the chemotherapy. Docetaxel was preceded by premedication with oral dexamethasone 7.5 mg q 12 h for 3 days starting 1 day before infusion to prevent hypersensitivity reactions and to reduce docetaxelrelated toxic skin effects and fluid retention.
In this study, treatment with IMRT was mandatory, all the patients were immobilized in the supine treatment position with head, neck and shoulder thermoplastic masks. Intravenous contrastenhanced CT using a slice thickness of 3-5 mm was performed for treatment planning. For target delineation, image fusion of the gadolinium-enhanced MRI T1 sequences with the CT simulation images was performed. The GTV_P and involved lymph nodes (GTV_N) included all gross tumors found on clinical and imaging examination. For the GTV_P, involved retropharyngeal lymph nodes were delineated according to the post-IC volume; intracavity lesions were not delineated if they exhibited regression, while involved tissues (e.g. muscles or bones) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation. The high-risk clinical target volume (CTV) included the nasopharynx, retropharyngeal lymph node, skull base, entire clivus, pterygoid fossa, parapharyngeal space, entire sphenoid sinus, posterior one-third of the nasal cavity and maxillary sinus, and drainage of the upper neck (levels II, III and Va). The low-risk CTV included the drainage of the lower neck (levels IV and Vb). Critical normal structures, including the brain stem, spinal cord, optic nerves, chiasm, lens, eyeballs, temporal lobes, larynx and parotid glands, were carefully delineated. The prescribed dose was 66-70. 4 Gy to the planning target volume of the nasopharynx (PTV_G: GTV_P +5 mm) and 66 Gy to the planned target volume of the lymph nodes (PTV_N: GTV_N +5 mm) in 32 fractions. The PTV60 covering the high-risk CTV and a 5-mm margin was prescribed 60 Gy/32 F. The PTV54 covering the low-risk CTV and a 5-mm margin was prescribed 54 Gy/32 F. All the patients were irradiated with one fraction daily, 5 days per week.
The dose-volume histograms (DVHs) of the treatment targets and critical normal structures were evaluated in accordance with the Radiation Therapy Oncology Group 0225 protocol (17) . The planning goal was to cover the prescribed doses as far as possible for the GTV_P without exceeding the dose tolerance of the critical neurologic OAR. The ideal maximal point doses were less than 45 Gy for the spinal cord, 54 Gy for the brain stem, optic chiasma and optic nerves, and 60 Gy for the temporal lobes. If these constraints could not be fulfilled, acceptable alternative doses were as follows: <50 Gy to 1 cc for the spinal cord; <60 Gy to 1% volume for the brain stem, optic chiasma and optic nerves; and <65 Gy to 1% volume for the temporal lobes. The dosimetric parameters for each patient were obtained from the DVH, including the maximum point dose (D max ), mean dose (D mean ), D min , maximum point dose to 1% volume (D 1 ) and percent target volume covered by the 95% prescribed dose line (V 95 ).
Clinical evaluation and follow-up
The local failure-free survival (LFFS), regional failure-free survival (RFFS), distant failure-free survival (DFFS) and overall survival (OS) were measured from the date of treatment to a documented event or last follow-up. Adverse events related to chemotherapy and radiotherapy were graded according to the National Cancer Institute Common Toxicity Criteria version 3.0. (18) and Radiation Therapy Oncology Group (19) , respectively. The assessment of tumor response was based on MRI according to the Response Evaluation Criteria for Solid Tumors criteria (20) .
A clinical evaluation was performed once per week during radiotherapy. After treatment completion, the patients were followed up every 3 months for years 1 and 2, every 6 months during years 3-5, and annually thereafter. Each follow-up included recording a medical history, a physical examination and nasopharyngoscopy. Enhanced MRI of the nasopharynx and neck areas was performed after IC, after radiotherapy, 3 months after radiotherapy, every 6 months for years 1 and 2, and annually thereafter. A chest X-ray/ CT and ultrasonography/CT of the abdomen were conducted once yearly. Additional tests (e.g. bone emission CT or Positron Emission Tomography-CT) were ordered whenever clinically indicated.
Statistics SPSS 22.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. The time-to-event data were described using Kaplan-Meier curves, and the differences were compared using the log-rank test. The logistic regression analysis was used to evaluate the relationship between dosimetric data and local failure. A receiver operating characteristic (ROC) curve analysis was applied to evaluate different cut-off points of D min to determine the appropriate D min to the GTV_P for clinical application. The patients were then stratified according to the optimal cut-off point. Differences in response rate according to D min status were tested for statistical significance with the Chi-square test for categorical variables. Multivariate analyses of significant factors were conducted using the Cox proportional hazards model. The survival curves were generated using GraphPad Prism, version 6.0 (GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered to be statistically significant.
Results
Patient characteristics
Between January 2009 and November 2013, 96 patients with T3-4 disease were enrolled. The median age was 46 years (range, 21-67 years). The details are listed in Table 1 . All the patients received TPF IC, with one cycle in two patients (2.0%) and two cycles in 94 patients (98.0%). One patient who experienced Grade 4 myelosuppression with a poor physical status changed the regimen to PF for the second cycle, and the other patient refused to continue the chemotherapy. Seventy-seven patients (80.2%) received TPF AC. The actual cycles of AC delivered were one cycle in 12 patients (12.5%) and two cycles in 65 patients (67.7%). The most frequent reasons for the discontinuation of AC were myelosuppression, a poor performance status and patient refusal due to complete response (CR) of the disease.
Dose statistics
The median overall radiation treatment time was 45 days (range, 40-59 days). Most patients (99%) completed the IMRT as prescribed except for one who discontinued therapy at the 63. Table 2 illustrates the DVH statistics for the neurologic structures. Dose exceeding the constraints were rare, but the affected sides of neurological structures usually received higher doses than the unaffected sides because of their closer proximity to the primary tumor. The average D max and D 1 to the affected optic nerve were 52.0 Gy and 51.8 Gy, respectively, while these values for the unaffected optic nerve were 51.4 Gy and 50.8 Gy, respectively. All sides of the temporal lobes were maintained within the dose constraints, except in four patients whose D 1 of the affected temporal lobes slightly exceeded the criteria, with 65.0 Gy, 65.2 Gy, 65.3 Gy and 65.8 maximum doses to the 1% volume, respectively. Among these patients, one had T3 disease, and the other three had T4 disease.
Treatment outcomes
The response of the nasopharyngeal lesions and cervical lymph nodes were evaluated by nasopharyngoscopy and MRI. After two cycles of IC, two patients (2.1%), 83 patients (86.5%) and 11 patients (11.5%) exhibited a local complete response (LCR), a local partial response (LPR) and local stable disease (LSD), respectively. Local progression of disease (LPD) was not observed. By the end of radiotherapy, 72 patients (75.0%) had a LCR, and 24 patients (25.0%) had a LPR. The overall response (LCR plus LPR) rate was 100%. Three months later, 93 patients (96.9%) achieved a LCR, and three patients (3.1%) remained with a LPR. The three LPR patients eventually developed LPD after 8 months, 23 months and 30 months, respectively. Regarding regional response, 91 of 96 patients (94.8%) were present with cervical lymph nodes at diagnosis. After IC, two patients (2.2%), 80 patients (87.9%) and nine patients (9.9%) exhibited a regional complete response (RCR), a regional partial response (RPR) and regional stable disease (RSD), respectively. By the end of radiotherapy, 69 patients (75.8%) had a RCR, and 22 patients (24.2%) had a RPR. Except two patients remained RPR and developed RPD 7 months after treatment, all patients achieved a RCR within 6 months after treatment.
With a median follow-up of 48.5 months (range, 8-85 months), treatment failure was observed in 26 patients. Local recurrence occurred in nine patients, two of whom presented with T3 disease and seven of whom presented with T4 disease. All the recurrences were located within the radiation fields. Regional recurrence was found in six patients, and distant metastasis was found in 15 patients (four of these patients also had local recurrence or regional recurrence). Among the patients who developed distant metastasis, six had bone metastasis, three had liver metastasis, three had lung metastasis, and three had multiple organ metastasis. Twenty patients died: four from local recurrence, seven from distant metastasis, three from local recurrence and distant metastasis, two from a second primary malignancy and four from unknown causes. The resulting estimated 3-year LFFS, RFFS, DFFS and OS were 92.4%, 96.8%, 90.4% and 89.6%, respectively. As expected, doses received by the GTV_P were related with local control. Results from logistic regression analysis showed that decreasing D min was significantly related to local failure (Odds Ratio [OR] 0.849; 95% CI 0.737-0.978; P = 0.023), while D mean (P = 0.077) and D max (P = 0.073) were not statistically significant. The ROC curve used to determine the optimal D min cut-off indicated that a D min to the GTV_P =54.0 Gy had the highest prognostic importance (P = 0.023). The patients were then divided into two groups: patients who received a D min to the GTV_P <54.0 Gy and those who received a D min to the GTV_P ≥54.0 Gy. The LCR rate after IMRT was 52.4% in the former group and 81.3% in the latter group (χ 2 = 7.335, P = 0.007). The 3-year LFFS of 78.4% for patients in the former group was significantly lower than the 95.9% for patients in the latter group (P = 0.005, Fig. 1A ). The 3-year OS rates were 75.9% and 93.3% for patients in the former group and in the latter group, respectively (P = 0.003, 
Acute and late toxicities
Mild to moderate acute and late toxicities were documented in the majority of patients. For patients who received chemotherapy with the TPF regimen, leukopenia was the primary acute toxicity. During IC, Grade 3 and Grade 4 leukopenia were observed in 14.6% and 7.3% of the patients, respectively. The incidence was increased during AC with Grade 3 in 24.7% of the patients and Grade 4 in 14.3% of the patients. No other acute Grade 3-4 hematologic toxicity was seen in any patient during chemotherapy. The most common acute toxicities during radiation were Grade 0-2. Grade 3 acute mucositis occurred in 27.1% of the patients. No Grade 4 acute toxicities were observed. Late toxicities in the central nervous system were documented regularly before recurrence or at the last follow-up for patients with or without local recurrence. One patient developed asymptomatic temporal lobe necrosis detected by MRI 42 months after IMRT in the affected side within the previous planned isodose line of 60-63 Gy. No other neurological dysfunction, such as brain stem injury, spinal cord injury or cranial nerve palsy, was documented. Details are listed in Table 3 .
Discussion
IMRT is a major step forward in the treatment of NPC, but advanced T-stage (T3-4) patients had a worse therapeutic gain from IMRT than early T-stage (T1-2) patients. Prospective and retrospective studies have also found that a step of elevation in advanced T-stage disease resulted in an~10% increase in the risk of local failure (12, 21) . This was probably due to the fact that the vast majority T3-4 disease presented with intracranial invasion or wide skull base erosion, and dose escalation was not applicable considering the surrounding neurologic structures. Therefore, treatment of IMRT for T3-4 NPC patients is trapped in a dilemma. Hara et al. (22) concluded from previous studies and their own experience that the local failure rate was still >10% in NPC patients with stage T3-4 disease despite IMRT. Wolden et al. (5) published their experience with IMRT in 38 T3-4 NPC patients who had a 3-year LFFS rate of 83%. Furthermore, Lai et al. (6) reported a 5-year LFFS rate of 87.5% for patients with stage T3-4 tumors treated with IMRT. In our study, we observed a 3-year LFFS rate of 92.4%, which was quite satisfactory compared with the above previous studies. We may attribute part of that result to the effective chemotherapy applied in our series.
The application of IC is beneficial for the local control of NPC because IC shrinks the primary tumor to produce a wider margin for irradiation, especially for bulky local disease with intracranial extension. Lee et al. (23) reported that IC conferred a response (LCR plus LPR) rate of 72% with the GTV_P reduced by an average of 61%, thus significantly improving the D min and consequent local control (P = 0.002). Additionally, IC is better tolerated with less severe toxic effects than concurrent chemoradiotherapy, as reported by Xu et al. (24) . In our study, we observed a response (LCR plus LPR) rate of 88.6% after IC, and only 21.9% of the patients experienced Grade 3/4 leukopenia during treatment.
Therefore, the efficacy and compliance of IC is quite satisfactory. The application of chemotherapy with the TPF regimen resulted in a better survival benefit than other regimens in head and neck cancer (25) . In the present study, the TPF regimen was implemented as well, and AC was added to consolidate therapy and decrease distant metastases. The adoption of IMRT without concurrent chemotherapy made it feasible to administer TPF in both neoadjuvant and adjuvant phases with a well-tolerated toxicity profile, according to previous experience at our institution (26) .
It has long been supposed that a higher D min to the GTV_P is related to better local control. However, with the tumor located so close to critical neurologic structures in advanced T-stage NPC, increasing the D min to the GTV_P was difficult to accomplish. Although Kwong et al. (14) escalated the prescribed dose to 76 Gy to the GTV_P for patients with T3-4 NPC, the resulting minimal D min to the GTV_P was 37.5 Gy. Ng et al. (27) reported a 5-year LFFS rate of 87.2% for T3 disease and 74% for T4 disease. The minimal D min to the GTV_P for T3 and T4 stage disease were 47.7 Gy and 29.9 Gy, respectively. Compared with the results of the above studies, higher minimal D min of 48.3 Gy to the GTV_P for T3-4 patients was achieved in our study, as well as better LFFS rates of 92.4%. It was believed that effective chemotherapy may lead to the shrinkage of the primary tumor, resulting in a wider margin between the tumor and OAR to enable an increase in the D min to the GTV_P. We further found that with effective chemotherapy, a D min to the GTV_P of no less than 54.0 Gy would not compromise the local control, which was confirmed by the multivariate analysis.
Treatment-related late injuries of neurologic structures remained a challenge for advanced T-stage NPC patients, who usually present with cranial nerve involvement and intracranial extension. Peng et al. (21) reported satisfactory 5-year LFFS rates of 91% for stage T3 and 81.5% for stage T4 disease in the IMRT group. In their study, the overall rates of temporal lobe necrosis, cranial nerve palsy and optic chiasm injury were 13.1%, 3.9% and 1.6%, respectively. However, they did not provide any information on dosimetric statistics. In a series of studies by Su et al. (28, 29) , the 5-year LFFS rates for T3 and T4 NPC patients were 88.6% and 80.5%, respectively. The recorded average maximum doses were 66.4-67.3 Gy, and the maximum point doses were 82.8-84.9 Gy to the temporal lobes. As a result, the incidences of temporal lobe injury were 3.1% and 13.4% in the T3 and T4 patients, respectively. In the present study, the average maximum doses and maximum point doses to the temporal lobes were 64.7-65.1 Gy and 67.6-68.4 Gy, respectively. Only one patient (1%) developed asymptomatic radiologic changes on MRI at 42 months after IMRT. The site of necrosis was within the previously planned isodose line of 60-63 Gy. The maximum dose delivered to the temporal lobe in this patient was 64 Gy. No other neurologic injuries were found. We attributed our few late toxicities to the stringent dose constraints for neurologic structures. Notably, we achieved LFFS rates of 96.3% and 87.4% in patients with T3 and T4 disease, respectively, and this result is not inferior to that reported above. Although patients in this study was prospectively enrolled and received unified treatment, there were still limitations. It was not a prospective clinical study, but only a prospective observational study, and the sample size was relatively small. Therefore, the present results can only be taken as preliminary. Furthermore, the patients were from a single institution and had a short follow-up time. Therefore, a randomized controlled study with a larger population of patients and a longer follow-up period to evaluate the long-term outcomes and complications is required.
Conclusion
The therapeutic margin of treating T3-4 disease is extremely narrow; therefore, an inadequate dose delivery was inevitable. A D min to the GTV_P ≥54.0 Gy may optimize the balance between local control and long-term neurologic injuries for T3-4 NPC treated with IMRT plus TPF chemotherapy. New ways to increase the D min to the GTV_P as far as possible without compromising neurological function and long-term quality of life are urgently required.
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